We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
aTyr Pharma Inc | NASDAQ:LIFE | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.04 | 2.41% | 1.70 | 1.67 | 1.72 | 1.7099 | 1.64 | 1.69 | 256,475 | 00:32:34 |
SAN DIEGO, Sept. 24, 2015 /PRNewswire/ -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced participation in two upcoming international scientific conferences:
International World Muscle (WMS) Congress 2015, Brighton, UK
September 30 – October 4, 2015
10th Annual International Symposium on Aminoacyl-tRNA Synthetases (AARS2015), Barcelona, Spain
October 18 – 22, 2015
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company's lead candidate, Resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. Resolaris™ is currently in a Phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (FSHD). Trials are planned in additional indications, including early onset FSHD and limb-girdle muscular dystrophy (LGMD) 2B. Trials are also planned for indications in interstitial lung disease (ILD). To protect this pipeline, aTyr built an intellectual property estate comprising 45 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by aTyr. aTyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation for which there are currently limited or no treatment options. For more information, please visit http://www.atyrpharma.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/atyr-pharma-announces-presentations-at-the-world-muscle-congress-and-10th-international-symposium-on-aminoacyl-trna-synthetases-aars2015-300148367.html
SOURCE aTyr Pharma, Inc.
Copyright 2015 PR Newswire
1 Year aTyr Pharma Chart |
1 Month aTyr Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions